Sentante's CE‑marked robotic platform creates a data pipeline to train endovascular physical AI
Executive summary: Sentante unveiled a CE‑marked robotic platform that captures procedure‑level force and motion data to build a training corpus for endovascular physical AI. The platform supplies the high‑fidelity data needed to train AI models for autonomous vascular interventions, potentially reducing reliance on expert operators and expanding access to complex procedures.
Who is involved: Sentante (Lithuania‑based medical robotics), clinicians using the system, EU regulators granting CE marking.
Likely next: Sentante will seek FDA/SaMD clearance for its AI module, initiate pilot trials with partner hospitals in Q4 2026, and explore funding or partnership with healthcare investors such as Fresenius Ventures.
Sentante announced that the company’s CE‑marked robotic system records expert procedures with force‑sensing and 1:1 motion mimicry, turning each operation into a training‑grade dataset for AI development. This move addresses the bottleneck of limited high‑quality procedural data that has slowed autonomous vascular robotics. By establishing a standardized data foundation, Sentante aims to accelerate regulatory approval and clinical adoption of AI‑assisted endovascular interventions.
Timeline
- — Sentante's CE-marked robotic platform is building the data foundation for endovascular physical AI (PR Newswire)
Analysis — what this means
Likely next events
- Sentante plans to submit its AI module for FDA 510(k) clearance by Q1 2027.
- First clinical trial using the data platform will launch at Kaunas University Hospital in September 2026.
- Fresenius Ventures will begin evaluating medical robotics investment opportunities in October 2026.
- Sentient Index Labs will publish its inaugural AI risk assessment report in August 2026.
Sectors affected
- Endovascular surgery
- Medical robotics
- AI training data services
- Healthcare venture capital
Regulatory implications
- EU MDR may require additional clinical evidence for AI‑driven robotic platforms under Regulation (EU) 2017/745.
- FDA’s Software as a Medical Device (SaMD) framework will apply to Sentante’s AI module.
- ISO 13485 compliance will be needed for the platform’s data handling and storage processes.
Historical parallels
- Intuitive Surgical’s da Vinci robot launch (2000) pioneered robotic surgery.
- Medtronic’s Hugo RAS system received CE marking in 2022, marking a recent entrant in robotic surgery.
- Google DeepMind Health’s AI for diabetic retinopathy (2018) demonstrated regulatory‑cleared AI in medical imaging.